Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Ovarian Neoplasms 3Mesothelioma, Malignant 3Solid Tumors 2Neoplasm Metastasis 2Disease Progression 2Colorectal Neoplasms 2Colonic Neoplasms 2Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Salivary Gland Neoplasms 1Parathyroid Neoplasms 1Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Kidney Neoplasms 1Head and Neck Neoplasms 1Esthesioneuroblastoma, Olfactory 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Medullary 1Carcinoma, Hepatocellular 1Advanced Solid Tumors 1Adenocarcinoma, Follicular 1

Interventions

Paclitaxel 15atezolizumab 11Gemcitabine 11Carboplatin 9pembrolizumab 8Docetaxel 8Bevacizumab 8Irinotecan 7Injections 6Cetuximab 6Capecitabine 6Sunitinib 5Leucovorin 5Fluorouracil 5Cyclophosphamide 5tocilizumab 4pazopanib 4olaparib 4navitoclax 4liposomal doxorubicin 4Topotecan 4Oxaliplatin 4Nivolumab 4Erlotinib Hydrochloride 4temsirolimus 3spartalizumab 3lenvatinib 3fludarabine 3cobimetinib 3Cisplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Solid Tumors × tumor necrosis factor-alpha, CNGRC fusion protein, human × Clear all
NCT00878111 2018-08-29

Study of NGR-hTNF Administered at High Doses in Patient With Advanced or Metastatic Solid Tumour

AGC Biologics S.p.A.

Phase 1 Completed
48 enrolled
Other solid neoplasm

Solid Tumors

NCT00483093 2014-05-30

Study of NGR-hTNF in Combination With Cisplatin in Solid Tumor

AGC Biologics S.p.A.

Phase 1 Completed
22 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡